DGAP-Adhoc

PLEDPHARMA PRESENTS TOP-LINE RESULTS FROM ITS PHASE IIb STUDY - PLEDOX(r) REDUCES NERVE DAMAGE IN CONJUNCTION WITH CHEMOTHERAPY BY 43 PERCENT - Seite 3

oxaliplatin.

ABOUT PLEDOX(r)

PledOx(r) is developed to prevent nerve damage caused by chemotherapy in cancer
treatment. The active substance calmangafodipir is a New Chemical Entity (NCE)
and has been shown in preclinical studies to protect human cells against
oxidative stress; a condition caused by formation of reactive oxygen and
nitrogen compounds during e.g. chemotherapy. Oxidative stress may, among other
things, cause damage to the sensory nerves (neuropathy). PledOx(r) mimics the
endogenous enzyme MnSOD, which represents the cell's intrinsic protection
against oxidative stress.

ABOUT NERVE DAMAGE CAUSED BY CHEMOTHERAPY IN COLORECTAL CANCER

Treatment with the cytotoxic drug oxaliplatin, one of the components in FOLFOX
combination chemotherapy, will often cause neuropathy i.e. hypersensitivity to
cold, problems with fine motor skills and pain. This side effect leads to
reduction in chemotherapy dose in 40 percent of patients and is the most common
reason for premature discontinuation of this cancer chemotherapy. Neuropathy is
often transient, but about 15-20 percent of patients experience persistent
problems, especially severe pain in hands and feet. There is currently no cure
for neuropathy.

ABOUT PLEDPHARMA
Pledpharma develops new drugs that protect the body against oxidative stress -
a condition that can be caused by chemotherapy and acetaminophen (paracetamol)
poisoning. The company's most advanced project PledOx(r) reduces nerve damage
associated with chemotherapy. The drug candidate Aladote(tm) is being developed to
reduce the risk of acute liver failure associated with acetaminophen poisoning.
The project PP-099 seeks to limit the damage that occurs to the heart muscle
during myocardial infarction. PledPharma's drug candidates are based on the
further development of a substance that, for completely different purposes,
already has been used by more than 200 000 patients. This may limit the
development risk and simplify the approval process. Pledpharma (STO: PLED) is
listed on Nasdaq First North. Erik Penser Bankaktiebolag is the company's
Certified Adviser. For more information, see www.pledpharma.se

PledPharma AB discloses the information provided herein pursuant to the Swedish
Securities Markets Act and/or the Swedish Financial Instruments Trading Act

Click on, or paste the following link into your web browser, to view the associated documents

https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=509502

News Source: NASDAQ OMX



29.03.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: PledPharma AB


Sweden
Phone:
Fax:
E-mail:
Internet:
ISIN: SE0003815604
WKN:

End of Announcement DGAP News-Service

---------------------------------------------------------------------------